News headlines about Inogen (NASDAQ:INGN) have trended somewhat positive this week, according to Accern. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Inogen earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned news headlines about the medical technology company an impact score of 45.385562875538 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

A number of research firms have recently issued reports on INGN. BidaskClub cut shares of Inogen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Needham & Company LLC reiterated a “buy” rating and issued a $108.00 target price on shares of Inogen in a research note on Friday, September 1st. Zacks Investment Research cut shares of Inogen from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Piper Jaffray Companies reiterated a “hold” rating and issued a $90.00 target price on shares of Inogen in a research note on Tuesday, September 12th. Finally, J P Morgan Chase & Co lifted their target price on shares of Inogen to $102.00 and gave the company an “overweight” rating in a research note on Monday, June 26th. Four investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. Inogen currently has a consensus rating of “Buy” and an average price target of $90.80.

Inogen (NASDAQ:INGN) traded down 0.22% on Tuesday, hitting $93.97. 49,496 shares of the stock were exchanged. Inogen has a 1-year low of $50.24 and a 1-year high of $105.35. The company has a market capitalization of $1.95 billion, a PE ratio of 81.57 and a beta of 1.00. The company has a 50-day moving average price of $98.26 and a 200 day moving average price of $90.98.

Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.28 by $0.10. The business had revenue of $64.10 million for the quarter, compared to analyst estimates of $59.99 million. Inogen had a net margin of 10.36% and a return on equity of 12.45%. The firm’s revenue for the quarter was up 17.4% on a year-over-year basis. During the same quarter last year, the business posted $0.25 EPS. Analysts anticipate that Inogen will post $1.21 EPS for the current fiscal year.

In related news, EVP Alison Bauerlein sold 6,667 shares of the stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $92.64, for a total transaction of $617,630.88. Following the sale, the executive vice president now owns 15,000 shares in the company, valued at approximately $1,389,600. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Raymond Huggenberger sold 14,000 shares of the stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $91.67, for a total transaction of $1,283,380.00. Following the sale, the director now owns 7,808 shares in the company, valued at approximately $715,759.36. The disclosure for this sale can be found here. Insiders have sold a total of 59,667 shares of company stock worth $5,724,661 in the last quarter. 5.31% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/17/inogen-ingn-earns-daily-coverage-optimism-score-of-0-10.html.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Stock Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related stocks with our FREE daily email newsletter.